Manipal Health IPO Draws Scrutiny Over Premium Valuation and Regional Concentration
India’s second-largest hospital chain is approaching public markets with strong top-line growth, but steep valuation multiples and recent margin compression may give institutional investors pause.
Manipal Health Enterprises is moving toward an initial public offering, positioning itself as the second-largest hospital chain in India by bed capacity and facility count as of March 2026. However, the offering is drawing caution from market participants due to an aggressive pricing structure and recent margin compression.
The company is seeking a price-earnings multiple of 85 based on its FY26 net profit and post-IPO equity. This represents a significant premium over established peers like Apollo Hospitals Enterprise, Max Healthcare Institute, and Fortis Healthcare, which currently trade at multiples between 62 and 68.
Top-line figures show robust expansion over the past two years. Revenue from operations grew at an annual rate of 29.4 percent to reach ₹10,335.8 crore between FY24 and FY26. During the same period, earnings before interest, tax, depreciation and amortisation climbed 24.8 percent to ₹2,644.1 crore.
Recent annual data reveals underlying stress despite this broader growth trend. In FY26 alone, while revenue rose 25.4 percent and EBITDA increased 22.1 percent year-on-year, net profit declined by 15.3 percent. Consequently, the EBITDA margin contracted to 25.6 percent in FY26, down from 27.5 percent in FY24.
Operational metrics highlight the sources of this financial pressure. The hospital network’s occupancy rate fell to 64.5 percent in FY26, down from 67.1 percent the previous year. Average revenue per occupied bed did manage a 5.7 percent annual increase to ₹68,937.61 over the FY24 to FY26 period, while operating cash flow grew 32.4 percent to ₹2,078.4 crore in FY26.
Investors are also weighing structural risks beyond the immediate financial statements. Approximately 46 percent of the company’s revenue is derived from Karnataka, indicating a heavy geographic concentration. Following the share sale, the promoter group’s stake will decrease to 72.1 percent from its current 81.4 percent.
Incorporated in 2010 under the Manipal Group, the provider offers tertiary and quaternary care ranging from organ transplants to oncology. Given the steep valuation and recent profit decline, market professionals are likely to wait for post-listing clarity before committing capital to the healthcare provider.
